Polymeric nano-micelles: Versatile platform for targeted delivery in cancer

Therapeutic Delivery

Volumn 5, Issue 10, 2014, Pages 1101-1121

  Mohamed, Salma ^a   Parayath, Neha N ^a   Taurin, Sebastien ^a   Greish, Khaled ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; CARBOHYDRATE; CASEIN; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE; FIRTECAN; FOLIC ACID; MONOCLONAL ANTIBODY; NC 4016; NC 6004; NK105; NK911; PACLITAXEL; PEPTIDE; POLOXAMER; SP1049C; TRANSFERRIN; UNCLASSIFIED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; DRUG CARRIER; MICELLE; NANOPARTICLE; POLYMER;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG TARGETING; ENHANCED PERMEABILITY AND RETENTION EFFECT; HYDROPHOBICITY; MICELLE; NANOMEDICINE; POLYMERIZATION; REVIEW; THERAPY; TUMOR CELL; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; PARTICLE SIZE; PHARMACEUTICS; PROCEDURES; SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MICELLES; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84912567965     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.69     Document Type: Review

References (136)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric micelles in anticancer therapy. targeting, imaging and triggered release. Pharm. Res. 27(12), 2569-2589 (2010).
3. Tan C, Wang Y, Fan W. Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies. Pharmaceutics 5(1), 201-219 (2013).
4. Lavasanifar A, Samuel J, Kwon GS. Poly (ethylene oxide)- block-poly (l-amino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 54(2), 169-190 (2002).
5. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24(1), 1-16 (2007).
6. Kulthe SS, Choudhari YM, Inamdar NN, Mourya V. Polymeric micelles: authoritative aspects for Drug delivery. Des. Monomers Polym. 15(5), 465-521 (2012).
7. Jones M-C, Leroux J-C. Polymeric micelles-a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 48(2), 101-111 (1999).
8. Kim S, Shi Y, Kim JY, Park K, Cheng J-X. Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin. Drug Deliv. 7(1), 49-62 (2010).
9. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112(3), 630-648 (2006).
10. Osada K, Christie RJ, Kataoka K. Polymeric micelles from poly (ethylene glycol)-poly (amino acid) block copolymer for drug and gene delivery. J. R. Soc. Interface 6(Suppl. 3), S325-S339 (2009).
11. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res. 24(6), 1029-1046 (2007).
12. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6(6), 714-729 (2010).
13. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target 15(7-8), 457-464 (2007).
14. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17), 812-818 (2006).
15. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65(1), 271-284 (2000).
16. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine 5(4), 523-528 (2010).
17. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: Physiologic and clinical implications. Cancer 73(9), 2432-2443 (1994).
18. Zhang W, Shi Y, Chen Y, Ye J, Sha X, Fang X. Multifunctional Pluronic P123/F127 mixed polymeric micelles loaded with paclitaxel for the treatment of multidrug resistant tumors. Biomaterials 32(11), 2894-2906 (2011).
19. Syu WJ, Yu HP, Hsu CY et al. Improved photodynamic cancer treatment by folate-conjugated polymeric micelles in a KB xenografted animal model. Small 8(13), 2060-2069 (2012).
20. Zhang P, Hu L, Yin Q, Feng L, Li Y. Transferrin-modified c [RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol. Pharm. 9(6), 1590-1598 (2012).
21. Oba M, Fukushima S, Kanayama N et al. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing αvβ3 and αvβ5 integrins. Bioconjug. Chem. 18(5), 1415-1423 (2007).
22. Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W. Cyclic RGD conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control. Release 143(1), 136-142 (2010).
23. Jin E, Zhang B, Sun X et al. Acid-active cell-penetrating peptides for in vivo tumor-targeted drug delivery. J. Am. Chem. Soc. 135(2), 933-940 (2013).
24. Chung EJ, Cheng Y, Morshed R et al. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials 35(4), 1249-1256 (2014).
25. Ma PA, Liu S, Huang Y, Chen X, Zhang L, Jing X. Lactose mediated liver-targeting effect observed by ex vivo imaging technology. Biomaterials 31(9), 2646-2654 (2010).
26. Jeong Y-I, Seo S-J, Park I-K et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly (γ-benzyl L-glutamate) and poly (ethylene glycol) diblock copolymer endcapped with galactose moiety. Int. J. Pharm. 296(1), 151-161 (2005).
27. Srivastava A, O'connor IB, Pandit A, Gerard Wall J. Polymer-antibody fragment conjugates for biomedical applications. Prog. Polym. Sci. 39(2), 308-329 (2014).
28. Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59(2), S21-S26 (2004).
29. Liao C, Sun Q, Liang B, Shen J, Shuai X. Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur. J. Radiol. 80(3), 699-705 (2011).
30. Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl Acad. Sci. USA 100(10), 6039-6044 (2003).
31. Perche F, Patel NR, Torchilin VP. Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J. Control. Release 164(1), 95-102 (2012).
32. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9(7), 537-550 (2010).
33. Liu H, Zhu Z, Kang H, Wu Y, Sefan K, Tan W. DNA-based micelles: synthesis, micellar properties and size-dependent cell permeability. Chemistry 16(12), 3791-3797 (2010).
34. Wu Y, Sefah K, Liu H, Wang R, Tan W. DNA aptamer- micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. USA 107(1), 5-10 (2010).
35. Xu W, Siddiqui IA, Nihal M et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34(21), 5244-5253 (2013).
36. Stubbs M, Mcsheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 6(1), 15-19 (2000).
37. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J. Control. Release 82(1), 17-27 (2002).
38. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16(1), 122-130 (2005).
39. Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide)-modified poly (β-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol. Pharm. 2(5), 357-366 (2005).
40. Shenoy D, Little S, Langer R, Amiji M. Poly (ethylene oxide)-modified poly (β-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm. Res. 22(12), 2107-2114 (2005).
41. Chen W, Zhong P, Meng F et al. Redox and pH-responsive degradable micelles for dually activated intracellular anticancer drug release. J. Control. Release 169(3), 171-179 (2013).
42. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148(2), 135-146 (2010).
43. Stefanadis C, Chrysochoou C, Markou D et al. Increased temperature of malignant urinary bladder tumors in vivo. the application of a new method based on a catheter technique. J. Clin. Oncol. 19(3), 676-681 (2001).
44. Liu S, Tong Y, Yang Y. Thermally sensitive micelles self-assembled from poly (N-isopropylacrylamide-co-N, N-dimethylacrylamide)-b-poly (d, l-lactide-co-glycolide) for controlled delivery of paclitaxel. Mol. Biosyst. 1(2), 158-165 (2005).
45. Chung J, Yokoyama M, Yamato M, Aoyagi T, Sakurai Y, Okano T. Thermo-responsive drug delivery from polymeric micelles constructed using block copolymers of poly (N-isopropylacrylamide) and poly (butylmethacrylate). J. Control. Release 62(1), 115-127 (1999).
46. Liu G, Liu W, Dong C-M. UV-and NIR-responsive polymeric nanomedicines for on-demand drug delivery. Polym. Chem. 4(12), 3431-3443 (2013).
47. Chen C-J, Liu G-Y, Liu X-S, Li D-D, Ji J. Construction of photo-responsive micelles from azobenzene-modified hyperbranched polyphosphates and study of their reversible self-assembly and disassembly behaviours. New J. Chem. 36(3), 694-701 (2012).
48. Munshi N, Rapoport N, Pitt WG. Ultrasonic activated drug delivery from Pluronic P-105 micelles. Cancer Lett. 118(1), 13-19 (1997).
49. Gao Z-G, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J. Control. Release 102(1), 203-222 (2005).
50. Pruitt JD, Pitt WG. Sequestration and ultrasound-induced release of doxorubicin from stabilized Pluronic P105 micelles. Drug Deliv. 9(4), 253-258 (2002).
51. Greish K, Nagamitsu A, Fang J, Maeda H. Copoly (styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjug. Chem. 16(1), 230-236 (2005).
52. Maeda H, Ueda M, Morinaga T, Matsumoto T. Conjugation of poly (styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J. Med. Chem. 28(4), 455-461 (1985).
53. Greish K, Sawa T, Fang J, Akaike T, Maeda H. SMA- doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J. Control. Release 97(2), 219-230 (2004).
54. Daruwalla J, Nikfarjam M, Greish K et al. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles. Survival improvement and inhibition of liver metastases. Cancer Sci. 101(8), 1866-1874 (2010).
55. Greish K. The cooperative anticancer effect of dual styrenemaleic acid nano-miceller system against pancreatic cancer (2011). http://omicsonline.org/2157-7439/2157-7439-S4-004.php.
56. Masuda E, Maeda H. Host-mediated antitumor activity induced by neocarzinostatin and its polymer-conjugated derivative SMANCS in tumor-bearing mice. In: Neocarzinostatin. Maeda H et al. (Eds). Springer, NY, USA, 187-204 (1997).
57. De Kruif CG, Zhulina EB. κ-casein as a polyelectrolyte brush on the surface of casein micelles. Colloids Surf. A 117(1-2), 151-159 (1996).
58. Zhen X, Wang X, Xie C, Wu W, Jiang X. Cellular uptake, antitumor response and tumor penetration of cisplatin-loaded milk protein nanoparticles. Biomaterials 34(4), 1372-1382 (2013).
59. Elzoghby AO, Helmy MW, Samy WM, Elgindy NA. Micellar delivery of flutamide via milk protein nanovehicles enhances its antitumor efficacy in androgen-dependent prostate cancer rat model. Pharm. Res. 30(10), 2654-2663 (2013).
60. Elzoghby AO, Samy WM, Elgindy NA. Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride. Pharm. Res. 30(2), 512-522 (2013).
61. Batrakova EV, Li S, Brynskikh AM et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J. Control. Release 143(3), 290-301 (2010).
62. Zhang Z, Tan S, Feng S-S. Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33(19), 4889-4906 (2012).
63. Kutty RV, Feng S-S. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials 34(38), 10160-10171 (2013).
64. Mi Y, Liu Y, Feng S-S. Formulation of docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (vitamin E TPGS2k) micelles for targeted and synergistic chemotherapy. Biomaterials 32(16), 4058-4066 (2011).
65. Mi Y, Zhao J, Feng S-S. Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. Int. J. Pharm. 438(1-2), 98-106 (2012).
66. Tsai H-C, Chang W-H, Lo C-L et al. Graft and diblock copolymer multifunctional micelles for cancer chemotherapy and imaging. Biomaterials 31(8), 2293-2301 (2010).
67. Gao Z, Lukyanov A, Chakilam A, Torchilin V. PEG-PE/phosphatidylcholine mixed immunomicelles specifically deliver encapsulated taxol to tumor cells of different origin and promote their efficient killing. J. Drug Target. 11(2), 87-92 (2003).
68. Gong J, Chen M, Zheng Y, Wang S, Wang Y. Polymeric micelles drug delivery system in oncology. J. Control. Release 159(3), 312-323 (2012).
69. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J. Drug Deliv 2013, 340315 (2013).
70. Yao H-J, Ju R-J, Wang X-X et al. The antitumor efficacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 32(12), 3285-3302 (2011).
71. Shapira A, Davidson I, Avni N, Assaraf YG, Livney YD. β-casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: Stability, target-activated release and cytotoxicity. Eur. J. Pharm. Biopharm. 80(2), 298-305 (2012).
72. Kumar R, Kulkarni A, Nagesha DK, Sridhar S. In vitro evaluation of theranostic polymeric micelles for imaging and Drug delivery in cancer. Theranostics 2(7), 714-722 (2012).
73. Li X, Qian Y, Liu T et al. Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging. Biomaterials 32(27), 6595-6605 (2011).
74. Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J. Natl Cancer Inst. 99(14), 1095-1106 (2007).
75. Kheirolomoom A, Mahakian LM, Lai C-Y et al. Copper-Doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol. Pharm. 7(6), 1948-1958 (2010).
76. Karathanasis E, Chan L, Balusu SR et al. Multifunctional nanocarriers for mammographic quantification of tumor dosing and prognosis of breast cancer therapy. Biomaterials 29(36), 4815-4822 (2008).
77. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J. Gene Med. 15(2), 65-77 (2013).
78. Ge Z, Chen Q, Osada K et al. Targeted gene delivery by polyplex micelles with crowded PEG palisade and cRGD moiety for systemic treatment of pancreatic tumors. Biomaterials 35(10), 3416-3426 (2014).
79. Oba M, Vachutinsky Y, Miyata K et al. Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble Flt-1. Mol. Pharm. 7(2), 501-509 (2010).
80. Vachutinsky Y, Oba M, Miyata K et al. Antiangiogenic gene therapy of experimental pancreatic tumor by sFlt-1 plasmid DNA carried by RGD-modified crosslinked polyplex micelles. J. Control. Release 149(1), 51-57 (2011).
81. Merdan T, Kopec Ek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev. 54(5), 715-758 (2002).
82. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-498 (2001).
83. Mao C-Q, Du J-Z, Sun T-M et al. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials 32(11), 3124-3133 (2011).
84. Sun T-M, Du J-Z, Yao Y-D et al. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. ACS Nano 5(2), 1483-1494 (2011).
85. Kim SC, Kim DW, Shim YH et al. In vivo evaluation of polymeric micellar paclitaxel formulation. toxicity and efficacy. J. Control. Release 72(1), 191-202 (2001).
86. Kim T-Y, Kim D-W, Chung J-Y et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 10(11), 3708-3716 (2004).
87. Kim D-W, Kim S-Y, Kim H-K et al. Multicenter Phase II trial of Genexol-PM, a novel cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 18(12), 2009-2014 (2007).
88. Lee KS, Chung HC, Im SA et al. Multicenter Phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108(2), 241-250 (2008).
89. Saif M, Rubin M, Figureueroa J, Kerr R. Multicenter Phase II trial of Genexol-PM (GPM), a novel Cremophor-free, polymeric micelle formulation of paclitaxel in patients with advanced pancreatic cancer (APC): final results. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25-27 January 2008.
90. United States National Library of Medicine, overview of clinical trials. (2014). http://clinicaltrials.gov/ct2/results?term=genexol&Search=Search
91. Koizumi F, Kitagawa M, Negishi T et al. Novel SN-38- incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res. 66(20), 10048-10056 (2006).
92. Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci. 99(6), 1258-1264 (2008).
93. Burris III H, Infante J, Spigel D et al. A Phase I dose-escalation study of NK012. J. Clin. Oncol. 26, 2538 (2008).
94. Hamaguchi T, Doi T, Eguchi-Nakajima T et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin. Cancer Res. 16(20), 5058-5066 (2010).
95. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv. Drug Deliv. Rev. 63(3), 184-192 (2011).
96. Hamaguchi T, Matsumura Y, Suzuki M et al. NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92(7), 1240-1246 (2005).
97. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci. 100(4), 572-579 (2009).
98. Kato K, Chin K, Yoshikawa T et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. New Drugs 30(4), 1621-1627 (2012).
99. Danson S, Ferry D, Alakhov V et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br. J. Cancer 90(11), 2085-2091 (2004).
100. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res. 56(16), 3626-3629 (1996).
101. Valle JW, Armstrong A, Newman C et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest. New Drugs 29(5), 1029-1037 (2011).
102. Cleare M, Hydes P, Malerbi B, Watkins D. Anti-tumour platinum complexes: relationships between chemical properties and activity. Biochimie 60(9), 835-850 (1978).
103. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin). active first-line therapy for patients with metastatic colorectal cancer. J. Clin. Oncol. 22(11), 2084-2091 (2004).
104. Du Bois A, Lück H-J, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst. 95(17), 1320-1329 (2003).
105. Uchino H, Matsumura Y, Negishi T et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br. J. Cancer 93(6), 678-687 (2005).
106. Plummer R, Wilson R, Calvert H et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 104(4), 593-598 (2011).
107. Nakanishi T, Fukushima S, Okamoto K et al. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 74(1), 295-302 (2001).
108. Matsumura Y, Hamaguchi T, Ura T et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 91(10), 1775-1781 (2004).
109. Cabral H, Murakami M, Hojo H et al. Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc. Natl. Acad. Sci. USA 110(28), 11397-11402 (2013).
110. United States National Library of Medicine, overview of clinical trials (2014). https://clinicaltrials.gov/ct2/results/browse?term=NC-4016&brwse=cond-alpha-all
111. Taurin S, Nehoff H, Greish K. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? J. Control. Release 164(3), 265-275 (2012).
112. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin. Drug Deliv. 7(2), 145-158 (2010).
113. Deng C, Jiang Y, Cheng R, Meng F, Zhong Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 7(5), 467-480 (2012).
114. De Menezes DEL, Hudon N, Mcintosh N, Mayer LD. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin. Cancer Res. 6(7), 2891-2902 (2000).
115. Lim HJ, Masin D, Mcintosh NL, Madden TD, Bally MB. Role of drug release and liposome-mediated Drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J. Pharmacol. Exp. Ther. 292(1), 337-345 (2000).
116. Jukanti R, Devraj G, Shashank AS, Devraj R. Biodistribution of ascorbyl palmitate loaded doxorubicin pegylated liposomes in solid tumor bearing mice. J. Microencapsul. 28(2), 142-149 (2011).
117. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI- 077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43(1), 1-7 (1999).
118. Xiong X-B, Huang Y, Lu W-L, Zhang H, Zhang X, Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm. Res. 22(6), 933-939 (2005).
119. Kaminskas LM, Mcleod VM, Kelly BD et al. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine 8(1), 103-111 (2012).
120. Soininen SK, Lehtolainen-Dalkilic P, Karppinen T et al. Targeted delivery via avidin fusion protein: Intracellular fate of biotinylated doxorubicin derivative and cellular uptake kinetics and biodistribution of biotinylated liposomes. Eur. J. Pharm. Sci. 47(5), 848-856 (2012).
121. Tagami T, Ernsting MJ, Li S-D. Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin. J. Control. Release 152(2), 303-309 (2011).
122. Unezaki S, Maruyama K, Ishida O, Suginaka A, Hosoda J-I, Iwatsuru M. Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly (ethylene glycol). Int. J. Pharm. 126(1-2), 41-48 (1995).
123. Gabizon AA. Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 16(2), 285-294 (1995).
124. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96(2), 273-283 (2004).
125. Kenmotsu H, Yasunaga M, Goto K et al. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 116(19), 4597-4604 (2010).
126. Peng C-L, Lai P-S, Lin F-H, Yueh-Hsiu Wu S, Shieh M-J. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 30(21), 3614-3625 (2009).
127. Rafi M, Cabral H, Kano M et al. Polymeric micelles incorporating (1, 2-diaminocyclohexane) platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis. J. Control. Release 159(2), 189-196 (2012).
128. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J. Control. Release 155(2), 272-281 (2011).
129. Zhou L, Cheng R, Tao H et al. Endosomal pH-activatable poly (ethylene oxide)-graft-doxorubicin prodrugs. synthesis, drug release, and biodistribution in tumor-bearing mice. Biomacromolecules 12(5), 1460-1467 (2011).
130. Duan X, Xiao J, Yin Q et al. Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram. ACS Nano 7(7), 5858-5869 (2013).
131. Wang X, Zhao G, Van S et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother. Pharmacol. 65(3), 515-526 (2010).
132. Colombo P-E, Boustta M, Poujol S et al. Biodistribution of doxorubicin-alkylated poly (l-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration. Eur. J. Pharm. Sci. 31(1), 43-52 (2007).
133. Song R, Joo Jun Y, Ik Kim J, Jin C, Sohn YS. Synthesis, characterization, and tumor selectivity of a polyphosphazene-platinum (II) conjugate. J. Control. Release 105(1), 142-150 (2005).
134. Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 42(5), 407-414 (1998).
135. Harada M, Murata J-I, Sakamura Y, Sakakibara H, Okuno S, Suzuki T. Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor-and tumor-bearing rats. J. Control. Release 71(1), 71-86 (2001).
136. Sugahara S-I, Kajiki M, Kuriyama H, Kobayashi T-R. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J. Control. Release 117 (1), 40-50 (2007).